YT 146

Drug Profile

YT 146

Alternative Names: YT146

Latest Information Update: 16 Nov 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Toa Eiyo
  • Developer Toa Eiyo; Yamasa Corporation
  • Class Anti-ischaemics; Antihypertensives; Vasodilators
  • Mechanism of Action Adenosine A2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Glaucoma; Reperfusion injury
  • Discontinued Hypertension

Most Recent Events

  • 16 Nov 2010 No development reported - Preclinical for Glaucoma in Japan (Ophthalmic)
  • 16 Nov 2010 No development reported - Preclinical for Reperfusion injury in Japan (IV)
  • 31 Jan 2008 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top